Literature DB >> 29655070

Development and external validation of a prediction rule for an unfavorable course of late-life depression: A multicenter cohort study.

O R Maarsingh1, M W Heymans2, P F Verhaak3, B W J H Penninx4, H C Comijs4.   

Abstract

BACKGROUND: Given the poor prognosis of late-life depression, it is crucial to identify those at risk. Our objective was to construct and validate a prediction rule for an unfavourable course of late-life depression.
METHODS: For development and internal validation of the model, we used The Netherlands Study of Depression in Older Persons (NESDO) data. We included participants with a major depressive disorder (MDD) at baseline (n = 270; 60-90 years), assessed with the Composite International Diagnostic Interview (CIDI). For external validation of the model, we used The Netherlands Study of Depression and Anxiety (NESDA) data (n = 197; 50-66 years). The outcome was MDD after 2 years of follow-up, assessed with the CIDI. Candidate predictors concerned sociodemographics, psychopathology, physical symptoms, medication, psychological determinants, and healthcare setting. Model performance was assessed by calculating calibration and discrimination.
RESULTS: 111 subjects (41.1%) had MDD after 2 years of follow-up. Independent predictors of MDD after 2 years were (older) age, (early) onset of depression, severity of depression, anxiety symptoms, comorbid anxiety disorder, fatigue, and loneliness. The final model showed good calibration and reasonable discrimination (AUC of 0.75; 0.70 after external validation). The strongest individual predictor was severity of depression (AUC of 0.69; 0.68 after external validation). LIMITATIONS: The model was developed and validated in The Netherlands, which could affect the cross-country generalizability.
CONCLUSIONS: Based on rather simple clinical indicators, it is possible to predict the 2-year course of MDD. The prediction rule can be used for monitoring MDD patients and identifying those at risk of an unfavourable outcome.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depressive disorder; Older adults; Predictors; Prognosis

Mesh:

Year:  2018        PMID: 29655070     DOI: 10.1016/j.jad.2018.04.026

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

1.  Abnormalities in the default mode network in late-life depression: A study of resting-state fMRI.

Authors:  Joan Guàrdia-Olmos; Carles Soriano-Mas; Lara Tormo-Rodríguez; Cristina Cañete-Massé; Inés Del Cerro; Mikel Urretavizcaya; José M Menchón; Virgina Soria; Maribel Peró-Cebollero
Journal:  Int J Clin Health Psychol       Date:  2022-05-27

2.  Symptomatic and functional recovery in depression in later life.

Authors:  Rose M Collard; Sanne Wassink-Vossen; Aart H Schene; Paul Naarding; Peter Verhaak; Richard C Oude Voshaar; Hannie C Comijs
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-06-19       Impact factor: 4.328

3.  Prevalence and predisposing factors of depressive symptoms in patients with stable coronary artery disease: a cross-sectional single-center study.

Authors:  Yeshun Wu; Bin Zhu; Zijun Chen; Jiahao Duan; Ailin Luo; Ling Yang; Chun Yang
Journal:  Aging (Albany NY)       Date:  2019-06-17       Impact factor: 5.682

4.  Serum Levels of FGF21, β-Klotho, and BDNF in Stable Coronary Artery Disease Patients With Depressive Symptoms: A Cross-Sectional Single-Center Study.

Authors:  Yeshun Wu; Zijun Chen; Jiahao Duan; Kai Huang; Bin Zhu; Ling Yang; Lu Zheng
Journal:  Front Psychiatry       Date:  2021-01-21       Impact factor: 4.157

5.  Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice.

Authors:  Gonzalo Salazar de Pablo; Erich Studerus; Julio Vaquerizo-Serrano; Jessica Irving; Ana Catalan; Dominic Oliver; Helen Baldwin; Andrea Danese; Seena Fazel; Ewout W Steyerberg; Daniel Stahl; Paolo Fusar-Poli
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.